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Abstract 
Background: The detection of submicroscopic infections in low prevalence settings has become an increasingly 
important challenge for malaria elimination strategies. The current field rapid diagnostic tests (RDTs) for Plasmodium 
falciparum malaria are inadequate to detect low-density infections. Therefore, there is a need to develop more sensi-
tive field diagnostic tools. In parallel, a highly sensitive laboratory reference assay will be essential to evaluate new 
diagnostic tools. Recently, the highly sensitive Alere™ Malaria Ag P.f ELISA (HS ELISA) was developed to detect P. falci-
parum histidine-rich protein 2 (HRP2) in clinical whole blood specimens. In this study, the analytical and clinical per-
formance of the HS ELISA was determined using recombinant P. falciparum HRP2, P. falciparum native culture parasites, 
and archived highly pedigreed clinical whole blood specimens from Karen village, Myanmar and Nagongera, Uganda.
Results: The HS ELISA has an analytical sensitivity of less than 25 pg/mL and shows strong specificity for P. falciparum 
HRP2 when tested against P. falciparum native culture strains with pfhrp2 and pfhrp3 gene deletions. Additionally, the 
Z′-factor statistic of 0.862 indicates the HS ELISA as an excellent, reproducible assay, and the coefficients of variation 
for inter- and intra-plate testing, 11.76% and 2.51%, were acceptable. Against clinical whole blood specimens with 
concordant microscopic and PCR results, the HS ELISA showed 100% (95% CI 96.4–100) diagnostic sensitivity and 
97.9% (95% CI 94.8–99.4) diagnostic specificity. For P. falciparum positive specimens with HRP2 concentrations below 
400 pg/mL, the sensitivity and specificity were 100% (95% CI 88.4–100) and 88.9% (95% CI 70.8–97.6), respectively. The 
overall sensitivity and specificity for all 352 samples were 100% (CI 95% 96–100%) and 97.3% (CI 95% 94–99%).
Conclusions: The HS ELISA is a robust and reproducible assay. The findings suggest that the HS ELISA may be a use-
ful tool as an affordable reference assay for new ultra-sensitive HRP2-based RDTs.
Keywords: Plasmodium falciparum, Malaria, Enzyme-linked immunosorbent assay, Histidine-rich protein 2, 
Elimination
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  smita.das988@gmail.com 
1 Diagnostics Program, PATH, Seattle, WA, USA
Full list of author information is available at the end of the article
Page 2 of 8Jang et al. Malar J          (2018) 17:403 
Background
Malaria is a vector-borne disease of major public health 
relevance worldwide. In 2015, the World Health Organ-
ization (WHO) reported 212 million new cases and 
429,000 deaths, most of which were attributed to Plas-
modium falciparum [1]. Significant reductions, how-
ever, occurred from 2010 to 2015, leading to 21% and 
29% decreases in incidence and mortality, respectively 
[1]. These improvements in disease burden have been 
largely attributed to vector control, and improved and 
accessible diagnostics and treatment [1]. As a result, at 
least 21 countries are positioned for elimination with 
many others following suit [1, 2], but in order to main-
tain such progress, continued commitment to malaria 
control strategies will be required. In particular, the role 
of current diagnostics has become an increasingly impor-
tant issue as low density infections have been identified 
at high rates in low prevalence settings [2, 3]. These low 
density parasite infections serve as reservoirs and are 
predicted to make up 20–50% of human-to-mosquito 
transmission [4]. While RDTs and microscopy are con-
sidered the current diagnostic standards for malaria, the 
limit of detection (LoD) for each tool, 5 parasites/µL in 
expert reference laboratories and 20 parasites/µL more 
generally for blood film microscopy; 100–200 parasites/
µL and 800 picograms (pg)/mL histidine-rich protein 
2 (HRP2) for P. falciparum RDTs, is not sufficient for 
detecting low density infections [4–10]. Highly sensitive 
and specific field deployable diagnostic tools to detect 
low density infections may provide more accurate esti-
mates of ongoing malaria transmission as well as render 
case detection-based elimination strategies more effec-
tive. The Alere™ ultrasensitive P. falciparum HRP2-based 
RDT with a greater than tenfold improvement in limit-
of-detection for HRP2 over previously available RDTs 
was launched in April 2017 [11, 12]. The development 
and performance of these tools for low density infections 
also require complementary laboratory-based reference 
assays for the same analytes that can confirm perfor-
mance of these tests.
Currently available standard ELISAs for HRP2 do not 
attain low enough LoDs for HRP2 to serve as useful ref-
erence assays for new highly sensitive HRP2-based RDTs 
or to define HRP2 distributions in populations with a 
large proportion of low density infections [13, 14]. While 
suitably sensitive assays for HRP2 already exist, the plat-
forms are not readily available to laboratories outside the 
research context [11, 15]. A standard ELISA remains the 
most accessible platform to most laboratories. A novel 
highly sensitive Alere™ Malaria Ag Pf ELISA (HS ELISA) 
has been developed. The HS ELISA has a similar platform 
and protocol compared to current commercial P. falci-
parum HRP2-based ELISA kits, but requires a smaller 
volume of blood, 50 μL versus 100 μL, respectively, mak-
ing it an attractive reference tool for large-scale use in 
field laboratories. In this study, HS ELISA performance 
against P. falciparum HRP2 was characterized using P. 
falciparum recombinant HRP2, a panel of P. falciparum 
native culture specimens, and clinical whole blood speci-
mens from Myanmar and Uganda.
Methods
Human subjects research
All study participants provided consent for whole blood 
specimen collection as part of studies approved by insti-
tutional review boards (IRBs). Specimens from Karen 
Village (TOT), Myanmar were collected and approved 
by OxTREC (Reference No. 1017-13 and 1015-13), by 
Tak Community Advisory Board, and local village com-
mittees. Ugandan specimens from Nagongera were 
collected under a study approved by the University of 
California San Francisco (UCSF) (IRB No. 11-05995), 
Makerere University (IRB No. 2011-0167), and London 
School of Hygiene and Tropical Medicine (LSHTM) (IRB 
No. 5943). Prior to PATH (Seattle, Washington, USA) 
receiving the specimens, all specimens were delinked and 
anonymized for analysis as described in consent forms.
Highly sensitive Plasmodium falciparum ELISA (HS ELISA)
The presence or absence of P. falciparum HRP2 was 
determined by the Alere™ Malaria Ag P.f (HRP2) ELISA 
(HS ELISA) (Reference Number: 05EK10; Republic of 
Korea) according to the manufacturer’s guidelines. The 
HS ELISA kit includes a capture antibody-coated 96-well 
plate, sample diluent, conjugate diluent, 1st enzyme con-
jugate concentrate, 2nd enzyme conjugate concentrate, 
a cutoff calibrator, positive and negative controls, Tetra-
methylbenzidine (TMB) substrate, stop solution, washing 
buffer concentrate and adhesive plate film. Briefly, 50 µL 
of blood, calibrator and controls were added to capture 
antibody-coated wells in duplicate, that contain 50 µL of 
sample diluent and then incubated at 37  °C for 60  min. 
The wells were washed to remove unbound blood pro-
teins with washing buffer. The diluted 1st enzyme con-
jugate (100  μL) was then added and incubated for 1  h. 
After washing, incubation with the diluted 2nd enzyme 
conjugate was followed. A solution of TMB substrate was 
added after a final wash to remove unbound conjugate 
and the resultant color change was measured by Spec-
traMax i3x (Molecular Devices, Sunnyvale, California, 
USA). After subtracting absorbance value at 620 nanom-
eter (nm) from absorbance value at 450  nm, replicate 
signal values were averaged and the assay results were 
interpreted as positive or negative relative to the cutoff 
absorbance. The HS ELISA results were considered “pos-
itive” if the average absorbance value was equal or above 
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the calculated cutoff, “negative” if the average absorbance 
was below the calculated cutoff, or “discordant” if a single 
replicate absorbance value was above the cutoff (“posi-
tive”) whereas the other replicate absorbance value was 
below the cutoff (“negative”) with a coefficient of varia-
tion (CV) above 15%. Discordant results were retested on 
a new plate if adequate sample volumes were available.
Analytical sensitivity and specificity
To determine the analytical sensitivity of HRP2 by the 
HS ELISA, P. falciparum recombinant GST-W2 HRP2 
(rGST-W2) (Microcoat Biotechnologie GmbH, Bernried 
am Starnberger See, Germany; Catalog # 30081) was 
obtained and serially diluted twofold in negative whole 
blood (BioreclamationIVT, Hicksville, New York, USA) 
from 800 to 5  pg/mL HRP2. At first, the limit of blank 
(LoB) and limit of detection (LoD) were determined with 
results from ten assays according to the Clinical and 
Laboratory Standard Institute (CLSI) EP-17A guidance: 
LoB = meanblank + 1.645  (SDblank), LoD = LoB + 1.645 
 (SDlow concentration sample) [16]. LoB and LoD were deter-
mined to be 0.11 and 0.13 by absorbance, respectively. 
The cutoff calibrator was formulated on the basis of the 
calculated LoD in absorbance. Performance of the cali-
brator was then assessed by testing dilution samples in 
duplicate with a cutoff calibrator for thirteen ELISA runs 
and determining positive and negative for HRP2.
For analytical specificity, the following seven P. falci-
parum native culture strains were used for testing: ITG, 
W2, 3D7, Dd2, D10, HB3 from BEI Resources (Manas-
sas, Virginia, USA) and 3BD5 from National Institute of 
Allergy and Infectious Diseases (NIAID, Bethesda, Mary-
land, USA). The wild-type strains, ITG, W2, 3D7, contain 
both the pfhrp2 and pfhrp3 genes, whereas Dd2 and D10 
are pfhrp2−/pfhrp3+ and HB3 is pfhrp2+/pfhrp3−. The 
3BD5 strain lacks both pfhrp2 and pfhrp3 genes (double 
deletion). All culture strains were cultured in vitro at the 
PATH laboratory [17]. Synchronization of cultures was 
performed by sorbitol-treatment procedure [18]. Parasi-
taemia was measured by light microscopy with a 100× 
oil objective by two trained microscopists. All P. falcipa-
rum native culture strains were serially diluted twofold 
in negative whole blood (BioreclamationIVT, Hicksville, 
New York, USA) from 2000 to 0.01  p/µL and tested in 
duplicate by the HS ELISA. All specimens were stored at 
− 80 °C and thawed on ice during testing. For each dilu-
tion, a normalized absorbance ratio (NAR) was meas-
ured by dividing the calculated absorbance value with the 
average absorbance of the calibrator on the sample plate.
Reproducibility and variability
The reproducibility of the HS ELISA were determined 
by the Z′-factor statistical method [19]. The Z′-factor 
method measures suitability of an assay for high-
throughput screening by measuring and comparing the 
means and standard deviations of positive and negative 
controls. P. falciparum 3D7 (pfhrp2+, pfhrp3+) and P. 
falciparum 3BD5 (pfhrp2−, pfhrp3−) culture strains 
were used as the positive and negative controls respec-
tively. The Z′-factor experiment was performed with the 
positive (3D7) and negative (3BD5) controls diluted in 
negative whole blood and consisted of 20 positive and 20 
negative replicates tested on each day for 2 days. Calcu-
lated Z′-values between 0.5 and 1 indicated an excellent 
assay and values between 0 and 0.5 were considered as a 
marginal assay. The formula for the Z′-factor calculation 
is the following:
SD: standard deviation.
For assay variability, negative whole blood was pre-
pared with 3D7 infected red blood cells (RBCs) to a sin-
gle stock concentration of 8.23 p/µL. The stock specimen 
was stored at − 80 °C and thawed on ice before testing. 
The specimen was tested on each of 5 days, with ten rep-
licates per plate. The % CVs were calculated to describe 
intra- and inter-plate variability. A mean % CV at or 
below 15% for interplate variability and a mean % CV at 
or below 10% for intraplate variability suggested excellent 
consistency in assay results.
Diagnostic sensitivity and specificity
Clinical whole blood specimens were collected from 
asymptomatic study participants in Myanmar and 
Uganda, as previously described [11]. Both study sites 
were selected because they represent different malaria 
endemic settings; the asymptomatic P. falciparum infec-
tion rate was 1.9% in Myanmar (May–April 2015) and 
43% in Uganda (May–September 2015) [11]. In Myan-
mar, both children and adults were recruited during two 
consecutive routine household visits as part of a study to 
assess mass drug administration (MDA) for malaria elim-
ination [11]. In Uganda, children 6  months to 11  years 
and their primary givers were recruited across 100 ran-
dom households as part of an ongoing cohort study 
[11]. The study participants visited a health clinic every 
3 months for routine visits, at which venipuncture blood 
collection and microscopy were performed. Participants 
were recruited based on asymptomatic status, which was 
defined as body temperature less than 37.5 °C, no malaria 
treatment within the previous 60 days, and no other clin-
ical symptoms of malaria [11]. Venipuncture whole blood 
(1.5–2 mL in EDTA vacutainer tubes) was collected from 
Z
′-factor
= 1−
(
3 ∗ SD positive control + 3 ∗ SD negative control
)
/
(
mean positive control−mean negative control
)
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each participant [11]. The blood was aliquoted and frozen 
at −  80  °C in the field and transported frozen to PATH 
(Seattle, Washington, USA), where the samples were 
stored at temperatures − 80 °C until testing [11].
Diagnostic performance using clinical specimens was 
determined in two parts; first, P. falciparum positive and 
negative clinical specimens from Myanmar and Uganda 
were chosen based on P. falciparum microscopy and con-
firmed by qRT-PCR [11]. Second, P. falciparum positive 
clinical specimens from Uganda were selected based on 
qRT-PCR and previously characterized HRP2 concentra-
tions below 400 pg/mL [11], the LOD of the current com-
mercial Malaria Ag CELISA (Cellabs Pty. Ltd, Brookvale, 
New South Wales, Australia).
Plasmodium falciparum negative specimens were also 
from Uganda and chosen based on microscopy and con-
firmed by qRT-PCR. For part one, 300 specimens were 
selected, of which 100 positive specimens were from 
Uganda and 200 negative specimens from Myanmar. For 
part two, 60 specimens were tested, of which 30 speci-
mens were positive and 30 specimens were negative. 
Before HS ELISA testing, 120 µL of each specimen was 
taken from the master aliquot, randomized, and blinded 
to hide the identity of the sample from the test opera-
tor. These archived frozen whole blood specimens expe-
rienced no more than three freeze–thaw cycles before 
testing. Specimens were defrosted immediately prior to 
use and were stored on ice during testing. Each speci-
men was tested in duplicate. Specimen identification 
was subsequently unblinded to match test results to the 
reference method and determine HS ELISA diagnostic 
performance.
Statistical analysis
GraphPad Prism, version 6.0 (GraphPad, Califor-
nia, USA) was used for statistical analysis of HS ELISA 
absorbance values, analytical sensitivity and specificity, 
and reproducibility and variability studies. For diagnostic 
sensitivity and specificity using clinical specimens from 
Myanmar and Uganda, the sensitivity was calculated 
by (true positives)/(true positives + false negatives) and 
the specificity by (true negatives)/(true negatives + false 
positives). The 95% confidence intervals were measured 
by exact binomial method in Stata 14.2 (College Station, 
Texas, USA).
Results
Analytical sensitivity and specificity
A series of rGST-W2 HRP2 specimens ranging from 5 
to 800  pg/mL HRP2 and negative whole blood controls 
were tested in duplicate for 13 ELISA runs to character-
ize HS ELISA sensitivity. The results demonstrated that 
the HS ELISA was able reliably to detect 100% of whole 
blood specimens with 25 pg/mL HRP2 (Fig. 1). Four out 
of the 13 samples (30.8%) were positive at 10 pg/mL, and 
2 out of 13 samples (15.4%) were positive at 5 pg/mL. All 
negative controls lacked reactivity.
The analytical specificity of the HS ELISA was inves-
tigated using seven P. falciparum native culture strains 
(ITG, W2, 3D7, Dd2, D10, HB3 and 3BD5) and the 
results were analysed for normalized absorbance ratios at 
different parasite concentrations (Table 1). At 74.1 p/µL, 
the wild-type strains (3D7, ITG, W2) and hrp3 deletion 
strain (HB3) showed high ratios (31.8–40.1), whereas 
the hrp2 deletion strains (Dd2, D10) showed lower ratios 
(1.5–2.9) (Table 1). The parasite strain 3D7 was detected 
as low as 0.01 p/µL. Assay reactivity to the hrp2/hrp3 
double deletion strain (3BD5) was not observed in any of 
the parasite concentrations (Table 1). The HS ELISA was 
also capable of detecting wild type strains and the hrp3 
deletion strain as low as 0.01–0.9 parasites/µL and 0.1 
parasites/µL, respectively (Table 1).
Reproducibility and variability
Two independent experiments were performed using 
the Z′-factor statistical method to evaluate HS ELISA 
reproducibility. Using the mean and standard deviation 
values for P. falciparum 3D7 and P. falciparum 3BD5 
positive and negative replicate wells, the positive con-
trol % CV was 1.37% [standard deviation (SD): 0.02] and 
the negative control % CV was 9.72% (SD: 0.01). The 
average Z′-factor was 0.862. The inter-plate variability 
using Pf 3D7 strain showed a mean % CV of 11.76%. The 
Fig. 1 Analytical sensitivity of the Plasmodium falciparum HS ELISA 
for the detection of HRP2 in whole blood. Recombinant P. falciparum 
rGST-W2 HRP2 specimens at concentrations ranging from 5 to 
800 pg/mL were tested by HS ELISA in duplicate per run and over 
13 runs. The absorbances of each replicate per concentration were 
averaged and interpreted as positive or negative relative to the 
cutoff absorbance for each plate. The results were plotted based 
on the percentage of positive tests associated with each target 
concentration
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intra-plate variability, also using Pf 3D7, had a % CV of 
2.51%.
Diagnostic sensitivity and specificity
In part one, a total of 300 clinical whole blood specimens 
from malaria endemic areas were selected for evaluating 
HS ELISA diagnostic performance. Two-hundred P. fal-
ciparum negative specimens from Myanmar and 100 P. 
falciparum positive specimens from Uganda were chosen 
based on P. falciparum microscopy and qRT-PCR results. 
The parasitaemia in the positive specimens ranged from 
8.84 to 235,095.8  p/µL. The mean and median para-
sitaemia were 8205 p/µL and 1090 p/µL, respectively. 
The P. falciparum HRP2 concentrations in the positive 
specimens ranged from 25.2 to 14,600 pg/mL (14,600 pg/
mL was the upper LOD reported previously [11]). The 
mean and median HRP2 concentrations were 9999  pg/
mL and 10,851.3  pg/mL respectively. From the initial 
testing of the clinical specimens using the HS ELISA, 104 
specimens were positive, 173 specimens were negative, 
and 23 specimens were discordant. Of the discordant 
specimens that met the criteria for retesting, five lacked 
the volume in the master aliquot for retesting and were 
subsequently removed from the final sensitivity and spec-
ificity calculations. The remaining 18 specimens tested 
as negative after repeat testing. The HS ELISA sensitivity 
and specificity were 100% (CI 95% 96.4–100%) and 97.9% 
(CI 95% 94.8–99.4%) respectively (see Table 2).
Table 1 Normalized absorbance ratios of  seven Plasmodium falciparum native culture strains (ITG, W2, 3D7, HB3, Dd2, 
D10, 3BD5) for parasitaemia ranging from 0.01 to 2000 p/µL
The ITG, W2, and 3D7 strains have both hrp2 and hrp3 genes, HB3 is an hrp3 deletion strain, Dd2 and D10 are hrp2 deletion strains, and 3BD5 is an hrp2 and hrp3 
double strain
Parasitaemia (p/µL) Normalized absorbance ratio
ITG W2 3D7 HB3 Dd2 D10 3BD5
2000 43.9 44.1 40.1 31.8 40.1 31.8 0.8
666.7 44.1 44.1 40.1 31.8 32.2 23.5 0.8
222.2 44.0 44.0 40.1 31.8 10.0 7.3 0.8
74.1 32.1 37.3 40.1 31.8 2.9 1.5 0.8
24.7 16.0 19.2 40.2 28.9 1.0 0.7 0.8
8.2 6.2 8.0 31.3 13.7 0.8 0.6 0.8
2.7 2.5 3.4 17.0 6.0 0.9 0.9
0.9 1.5 1.9 7.5 3.0 0.8 0.8
0.3 0.9 1.2 3.5 1.6
0.1 0.8 0.9 2.3 1.0
0.03 0.8 0.9 1.5 0.8
0.01 0.7 0.9 1.3 0.5
Table 2 HS ELISA performance using Plasmodium falciparum positive and  negative clinical specimens from  Uganda 
and Myanmar that were (A) confirmed by composite microscopy and qRT-PCR and (B) confirmed by qRT-PCR and HRP2 
concentrations below 400 pg/mL
Panel A
Microscopy and qRT-PCR Sensitivity (95% CI) Specificity (95% CI)
Positive Negative
HS ELISA Positive 100 4 100% (96.4–100%) 97.9% (94.8–99.4%)
Negative 0 191
Panel B
qRT-PCR and HRP2 < 400 pg/mL Sensitivity (95% CI) Specificity (95% CI)
Positive Negative
HS ELISA Positive 30 3 100% (88.4–100%) 88.9% (70.8–97.6%)
Negative 0 24
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In part two, a total of sixty clinical whole blood speci-
mens from Uganda were tested for diagnostic perfor-
mance using the HS ELISA. Thirty specimens were P. 
falciparum positive by qRT-PCR and also had HRP2 
concentrations less than 400 pg/mL, and an additional 30 
specimens were P. falciparum negative based on concord-
ant microscopy and qRT-PCR. The P. falciparum positive 
specimens had parasitaemia ranging from 0.04 to 1158.8 
p/µL. The mean and median parasitaemia were 90.4 p/µL 
and 13.1 p/µL, respectively. The HRP2 concentrations in 
positive specimens ranged from 6.1 to 337.2 pg/mL. The 
mean and median HRP2 concentrations were 107.4  pg/
mL and 73.2  pg/mL, respectively. Of the 60 specimens 
tested initially using the HS ELISA, three specimens 
were discordant and had insufficient volume for retest-
ing; these specimens were excluded from performance 
measurements. The HS ELISA sensitivity and specificity 
were 100% (CI 95% 88.4–100%) and 88.9% (CI 95% 70.8–
97.6%), respectively (see Table 2).
Discussion
The RDTs and conventional ELISA-based assays are con-
sidered to be common methods for malaria detection in 
both field and laboratory settings, but are both restricted 
to detecting high HRP2 concentrations. While this has 
critical importance for identifying and treating acute P. 
falciparum malaria infections, the current challenge of 
detecting asymptomatic low density infections with cor-
respondingly low HRP2 levels has made these tools inad-
equate [2, 4, 20]. This is the first report of an analytical 
and diagnostic validation of a new highly sensitive HRP2-
based screening immunoassay against recombinant and 
native P. falciparum HRP2 strains and archived clinical 
whole blood specimens. Using multiple different speci-
men types provided a detailed characterization of HS 
ELISA performance, reproducibility, and variability.
The HS ELISA was shown to be a sensitive and robust 
assay. The HS ELISA was able to detect 100% of P. falcipa-
rum rGST-W2 HRP2 at 25 pg/mL, a 16-times improve-
ment over the commercial CELISA (LOD: 400  pg/mL 
rGST-W2 HRP2). While the HS ELISA was evaluated 
with rGST-W2 HRP2 an international reference standard 
for malaria diagnostic evaluations the analytical sensitiv-
ity may vary across other recombinant proteins as shown 
previously with the CELISA and other HRP2 assays [13–
15, 21].
The HS ELISA analytical sensitivity results also indi-
cated high assay reactivity to P. falciparum HRP2 across a 
wide range of low parasitaemias, 0.01–74.1 p/µL, as well 
as a panel of P. falciparum native culture strains with dif-
ferent pfhrp2 and pfhrp3 genotypes. The assay reactivity 
was the poorest with pfhrp2−/pfhrp3+ deletion strains 
(Dd2, D10) compared to wild-type (ITG, W2, 3D7) and 
pfhrp2+/pfhrp3− deletion strain (HB3). P. falciparum 
3BD5 strain, lacking both pfhrp2 and pfhrp3, was nega-
tive by HS ELISA. These findings correlate well with 
pfhrp2 and pfhrp3 genetic detection profiles, assum-
ing some cross-reactivity of the assay with HRP3 as 
demonstrated for other HRP2 tests. The reproducibility 
Z′-factor estimate (0.862) was within the range 0–0.5, 
indicating the HS ELISA as a robust and reproducible 
assay. The inter-assay and intra-assay variability were 
within the acceptable range of % CVs, less than 15% and 
less than 10%, respectively. Together, these results sug-
gest the HS ELISA to be a robust and reproducible assay. 
Additional studies are required to further expand the 
Z′-factor estimate, inter-assay and intra-assay variabil-
ity studies to other P. falciparum strains and in different 
locations. Parallel studies comparing the performances of 
conventional ELISAs and the new HS ELISA with P. falci-
parum recombinant and native culture strains would also 
further define the capacity of the HS ELISA to discrimi-
nate positive and negative results.
An ELISA that is able to detect low levels of P. falci-
parum HRP2 is a valuable reference assay to detect and 
confirm asymptomatic low density infections. These 
infections not only have low parasite densities, but also 
low HRP2 levels, and are thus difficult to identify with 
current field methods, RDT and microscopy [5–7, 22]. 
The recognition that more sensitive field tools are vital for 
continued success of malaria programmes has encour-
aged the development of next-generation diagnostic tests 
[2, 11]. The HS ELISA may serve as a reference tool to 
confirm the results of these novel diagnostics. Here, HS 
ELISA performance was characterized using clinical 
whole blood specimens from asymptomatic participants 
in Myanmar and Uganda, representing low and high 
transmission areas, respectively. Using these specimens, 
the HS ELISA sensitivity and specificity in Part 1, 100% 
and 97.9% respectively, and in Part 2, 100% and 88.9% 
respectively, were excellent. It should be noted especially 
for Part 2 because of the small sample size (n = 60) that 
three discordant specimens were excluded from analysis 
because of insufficient volume for re-testing, which could 
have biased the sensitivity or specificity measurements. 
Additionally, the clinical specimens were not tested for 
hrp2 and hrp3 deletions, which if present, would have 
likely influenced performance results. Future studies 
should recognize this limitation of the HS ELISA and test 
for hrp2 and hrp3 deletion parasites concurrently.
The utility of the HS ELISA could potentially extend 
beyond a reference test for malaria control and elimi-
nation programmes; the assay could be used also in 
drug sensitivity trials, possibly in blood bank screening, 
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though a negative would not guarantee complete absence 
of parasites, and other epidemiological studies [14, 23, 
24]. The performance and impact of the HS ELISA for 
these other applications should be investigated.
Conclusions
The HS ELISA demonstrated acceptable sensitivity and 
specificity for detecting P. falciparum HRP2, including 
recombinant protein, native culture P. falciparum para-
sites, and clinical whole blood specimens. This new assay 
will be useful in assessing new diagnostic tools and possi-
bly other malaria intervention trials due to its lower limit 
of detection of P. falciparum HRP2. With an increased 
number of reports of pfhrp2/pfhrp3 gene deletions 
resulting in false negative results, future work should 
focus on the development of a more sensitive ELISA to 
identify parasites with pfhrp2/pfhrp3 deletions and pos-
sibly other Plasmodium malaria species.
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